Fen-Phen: Daily Fen-Phen use was linked to valvular heart disease and pulmonary hypertension via 5-HT2B receptor agonism by fenfluramine's metabolite norfenfluramine; the combination was withdrawn from market in 1997. Nearly 30% of users taking the combination for up to 24 months developed abnormal
Related pages